Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study

Conclusion: Escalating incobotulinumtoxinA doses (400 U up to 800 U) did not compromise safety or tolerability, enabled treatment in a greater number of muscles/spasticity patterns, and was associated with increased treatment efficacy, improved muscle tone, and goal attainment. ClinicalTrials.gov identifier: NCT01603459. Classification of evidence: This study provides Class IV evidence that, for patients with limb spasticity, escalating incobotulinumtoxinA doses (400 U up to 800 U) increases treatment efficacy without compromising safety or tolerability.

http://www.neurology.org/cgi/content/short/88/14/1321?rss=1

Source: Neurology - April 3, 2017 Category: Neurology Authors: Wissel, J., Bensmail, D., Ferreira, J. J., Molteni, F., Satkunam, L., Moraleda, S., Rekand, T., McGuire, J., Scheschonka, A., Flatau-Baque, B., Simon, O., Rochford, E. T. J., Dressler, D., Simpson, D. M., On behalf of the TOWER study investigators Tags: Botulinum toxin, All Cerebrovascular disease/Stroke, All Rehabilitation, Patient safety ARTICLE Source Type: research